- $4.05bn
- $3.45bn
- $1.11bn
Alkermes Plc reports results for the quarter ended in September - Earnings Summary
Brief: Alkermes Q3 GAAP Loss Per Share $0.18
Brief: Alkermes Initiates Artistry-7 Phase 3 Trial Of Nemvaleukin Alfa In Patients With Platinum-Resistant Ovarian Cancer
Alkermes Plc expected to post earnings of 6 cents a share - Earnings Preview
Brief: Alkermes Receives FDA Fast Track Designation For Nemvaleukin Alfa In Combination With Pembrolizumab For Treatment Of Platinum-Resistant Ovarian Cancer
Brief: Alkermes Announces Commercial Availability Of Lybalvi®
U.S. RESEARCH ROUNDUP-Alkermes, Biomarin Pharmaceutical, Horizon Therapeutics
U.S. STOCKS ON THE MOVE-Square, Affirm, Foot Locker, Tesla, Robinhood
U.S. STOCKS ON THE MOVE-Square, Foot Locker, Immunovant, Bloomin' Brands, Affirm
Alkermes up on FDA's fast track status for cancer treatment
Brief: Alkermes Receives FDA Fast Track Designation For Nemvaleukin Alfa For The Treatment Of Mucosal Melanoma
U.S. RESEARCH ROUNDUP:-Equity Residential, Hess, O'Reilly Automotive
Alkermes Plc reports results for the quarter ended in June - Earnings Summary
Brief: Alkermes Q2 Revenue Rose 23 Percent To 303.7 Million USD
Alkermes Plc expected to post earnings of 12 cents a share - Earnings Preview
Baseball-Sabathia outdueled alcoholism, now he wants to inspire others
Brief: Alkermes Presents New Data On Nemvaleukin Alfa At 2021 American Society Of Clinical Oncology Annual Meeting
Brief: Alkermes Presents New Data On Nemvaleukin Alfa At 2021 American Society Of Clinical Oncology Annual Meeting
Brief: Alkermes Announces FDA Approval Of Lybalvi For The Treatment Of Schizophrenia And Bipolar I Disorder